Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
62.3M
-
Number of holders
-
37
-
Total 13F shares, excl. options
-
31.5M
-
Shares change
-
+15.3M
-
Total reported value, excl. options
-
$47.9M
-
Value change
-
+$22.1M
-
Number of buys
-
24
-
Number of sells
-
-10
-
Price
-
$1.52
Significant Holders of Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) as of Q2 2023
43 filings reported holding ELEV - Elevation Oncology, Inc. - Common stock, par value $0.0001 per share as of Q2 2023.
Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) has 37 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.5M shares
of 62.3M outstanding shares and own 50.59% of the company stock.
Largest 10 shareholders include TANG CAPITAL MANAGEMENT LLC (4M shares), venBio Partners LLC (2.91M shares), Aisling Capital Management LP (2.83M shares), ARMISTICE CAPITAL, LLC (2.4M shares), Qiming U.S. Ventures Management, LLC (2.37M shares), MILLENNIUM MANAGEMENT LLC (2.32M shares), BVF INC/IL (2.31M shares), ORBIMED ADVISORS LLC (1.5M shares), ExodusPoint Capital Management, LP (1.5M shares), and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.38M shares).
This table shows the top 37 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.